# Adrenaline for the Treatment of No-Reflow in Normotensive Patients

Study · id `cardio:ct-nct04699110` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04699110](<https://clinicaltrials.gov/study/NCT04699110>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04699110

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 201 participants.

## Technical summary

Registry record NCT04699110. Randomized; no masking; primary purpose treatment. Start 2021-01-01 (actual); primary completion 2021-04-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 201 participants (enrolled count; ClinicalTrials.gov record NCT04699110, source copy `cardio:ctgov-nct04699110-2021-05-21`, retrieved 2026-10-31)
- Started: 2021-01-01 (actual) (ClinicalTrials.gov record NCT04699110, source copy `cardio:ctgov-nct04699110-2021-05-21`, retrieved 2026-10-31)
- Primary completion: 2021-04-30 (actual) (ClinicalTrials.gov record NCT04699110, source copy `cardio:ctgov-nct04699110-2021-05-21`, retrieved 2026-10-31)
- Completion: 2021-04-30 (actual) (ClinicalTrials.gov record NCT04699110, source copy `cardio:ctgov-nct04699110-2021-05-21`, retrieved 2026-10-31)
- Countries: Pakistan (ClinicalTrials.gov record NCT04699110, source copy `cardio:ctgov-nct04699110-2021-05-21`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04699110-2021-05-21`, retrieved 2026-10-31)

## The registry's words

- Brief title: Adrenaline for the Treatment of No-Reflow in Normotensive Patients
- Condition: Acute Coronary Syndrome
- Condition: No-Reflow Phenomenon
- Condition: Normotensive
- Intervention (Drug): Adrenaline
- Intervention (Drug): Adenosine
- Lead sponsor: National Institute of Cardiovascular Diseases, Pakistan
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: National Institute of Cardiovascular Diseases, Pakistan (`cardio:org-national-institute-of-cardiovascular-diseases-pakistan`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Comparison of Intracoronary Epinephrine and Adenosine for No-Reflow in Normotensive Patients With Acute Coronary Syndrome (COAR Trial) (`cardio:pubmed-35000456`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 29fd885329691325e4bce86c729622e2e974978dd8d7a83c4031cddfa45b2af9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
